← Back to patent-cliff list
乙醇达芦那韦/考比司他
Tier C — Watch / tradeDarunavir Ethanolate/Cobicistat
强生创新制药
Originator
2014
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type
Targets：CYP3A、HIV-1 protease
Brand：普泽力、Rezolsta、Prezcobix
Indications (approved)：HIV感染
Regional status
US
批准上市
2015-01-29
EU
批准上市
2014-11-19
China
批准上市
2018-06-19
Japan
批准上市
2016-11-22
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Darunavir Ethanolate/Cobicistat?
Approved indications include: HIV感染.
When does the Darunavir Ethanolate/Cobicistat patent expire?
No public expiry year is available for Darunavir Ethanolate/Cobicistat yet; this page updates once verified.
How do I get a quote for Darunavir Ethanolate/Cobicistat intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24